Recently, attention has been drawn to the therapeutic potential of VIP for the clinical treatment of COPD/asthma on the basis that VIP acts as a neurotransmitter, the dominant mechanism of human airway and vascular relaxation, and its anti-inflammatory properties. This evidence concerns the gene VIP and chronic obstructive pulmonary disease.